Gargoyle Investment Advisor L.L.C. Purchases New Stake in Jazz Pharmaceuticals PLC (JAZZ)

Gargoyle Investment Advisor L.L.C. purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,323 shares of the specialty pharmaceutical company’s stock, valued at approximately $206,000.

Other institutional investors have also added to or reduced their stakes in the company. C WorldWide Group Holding A S raised its position in Jazz Pharmaceuticals PLC by 3.7% in the first quarter. C WorldWide Group Holding A S now owns 98,465 shares of the specialty pharmaceutical company’s stock valued at $14,290,000 after buying an additional 3,493 shares during the last quarter. Monarch Partners Asset Management LLC bought a new stake in Jazz Pharmaceuticals PLC during the first quarter worth about $8,733,000. Canada Pension Plan Investment Board raised its stake in Jazz Pharmaceuticals PLC by 587.5% in the first quarter. Canada Pension Plan Investment Board now owns 82,651 shares of the specialty pharmaceutical company’s stock worth $11,995,000 after buying an additional 70,629 shares in the last quarter. Wells Fargo & Company MN raised its stake in Jazz Pharmaceuticals PLC by 0.5% in the first quarter. Wells Fargo & Company MN now owns 503,759 shares of the specialty pharmaceutical company’s stock worth $73,111,000 after buying an additional 2,529 shares in the last quarter. Finally, Sumitomo Mitsui Asset Management Company LTD raised its stake in Jazz Pharmaceuticals PLC by 16.8% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 4,910 shares of the specialty pharmaceutical company’s stock worth $712,000 after buying an additional 707 shares in the last quarter. Institutional investors and hedge funds own 87.22% of the company’s stock.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 146.63 on Wednesday. The stock has a market capitalization of $8.81 billion, a price-to-earnings ratio of 22.59 and a beta of 1.10. The company’s 50 day moving average price is $154.13 and its 200 day moving average price is $147.45. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by $0.13. The company had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The company’s revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.67 earnings per share. On average, analysts expect that Jazz Pharmaceuticals PLC will post $10.87 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Gargoyle Investment Advisor L.L.C. Purchases New Stake in Jazz Pharmaceuticals PLC (JAZZ)” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/2823251/gargoyle-investment-advisor-l-l-c-purchases-new-stake-in-jazz-pharmaceuticals-plc-jazz.html.

JAZZ has been the topic of several research analyst reports. Cowen and Company reissued an “outperform” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, June 7th. BidaskClub upgraded Jazz Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Royal Bank Of Canada set a $210.00 price target on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Tuesday, June 27th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $182.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, June 7th. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, April 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $182.72.

In other news, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $150.65, for a total value of $30,130.00. Following the sale, the executive vice president now directly owns 22,223 shares of the company’s stock, valued at approximately $3,347,894.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Paul L. Berns sold 662 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $142.37, for a total transaction of $94,248.94. Following the completion of the sale, the director now directly owns 6,599 shares in the company, valued at $939,499.63. The disclosure for this sale can be found here. Insiders have sold a total of 12,366 shares of company stock worth $1,892,262 over the last three months. Insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.